Study investigates SARS-CoV-2 escape from nirmatrelvir

By | June 10, 2022
Researchers assessed SARS-CoV-2 Alpha, Delta, and Omicron variants’ resistance to nirmatrelvir, a protease inhibitor of SARS-CoV-2.